U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336472) titled 'A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma' on Jan. 08.
Brief Summary: This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma
Study Start Date: April 01, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: IBI3003
Participants will receive IBI3003 treatment until death...